Rentschler Biopharma SE. (5/27/20). "Press Release: Rentschler Biopharma Extends Collaboration with Genmab to U.S. Facility". Laupheim & Milford, MA.

	Organisation	Rentschler Biopharma Inc.
	Group	Rentschler (Group)
	Organisation 2	Genmab A/S (CSE: GEN, Nasdaq: GMAB)
	Group	Genmab (Group)
	Product	contract manufacturing (biologicals)
	Product 2	DuoBody product (bispecific antibody)
	Index term	Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility
	Index term 2	Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE
	Person	Pollano, Federico (Rentschler 201803– SVP BusDev before Polpharma Biologics + Richter-Helm + BioGeneriX)
	Person 2	Mathias, Frank (Oxford Biomedica 202203– CEO before Rentschler + Medigene + Amgen GmbH + Servier DE + Hoechst)

- Innovative agreement provides flexible model to address Genmab's development and manufacturing needs as programs advance in development

- Rentschler Biopharma's U.S. site expansion progressing on track with plans to significantly increase square footage and number of employees

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that the company has entered into a strategic collaboration with Genmab for the process development and manufacture of bispecific antibodies generated with Genmab's DuoBody(R) technology platform. This partnership uses an innovative business model which fits well with the expansion plans for Rentschler Biopharma's U.S. site in Milford, MA.

Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, said: "We are excited to expand our strategic partnership with Genmab, a leading biotech specializing in the creation and development of differentiated antibody therapeutics, to our U.S. facility. In this new age of personalized medicine, breakthrough molecules, and complex therapies, Rentschler Biopharma welcomes the opportunity to use innovation to empower our clients and ultimately help patients. The work we will do for Genmab at our U.S. site represents a first-of-its-kind collaboration that will involve several novel projects and enable the client to decide in a flexible and agile way which projects to advance and when."

U.S. site expansion making good progress

Rentschler Biopharma acquired its U.S. site in the greater Boston area in January 2019. The FDA, EMA and Health Canada licensed, 93,000 square foot facility will be qualified as a multi-product site offering clients innovative solutions. The first step in expanding Rentschler Biopharma's Center of Excellence in North America is a 500 L single-use bioreactor that will be operational by mid-2020. The next steps include another building for large-scale single-use manufacturing and lab capacity for new therapeutic modalities. The company plans to leverage its expertise for client projects through every phase, be it early-stage development or clinical and commercial production. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins. In total, Rentschler Biopharma intends to continuously invest in these expansions and to hire up to 75 additional people at the site to keep pace with the site development and business growth.

"We are grateful for the trust that Genmab has put in us based on our work for them at our Laupheim site. This extended collaboration with Genmab at our U.S. innovation hub is a perfect fit with our expansion. Our growth will enable us to support our partner at each step of the way as their plans advance and evolve," said Dr. Frank Mathias, CEO of Rentschler Biopharma. "Since acquiring the U.S site in 2019, we have accomplished a lot and are very pleased our expansion is moving forward as planned and on time. We look forward to bringing in additional innovative projects from both new and existing clients."

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,000 employees.

For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.

Contact:

Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
Phone: +49-7392-701-874
[email protected]

Media inquiries:
MC Services AG
Eva Bauer
Phone: +49-89-210228-0
U.S.
Laurie Doyle
Phone: +1-339-832-0752
[email protected]

Record changed: 2024-12-29